Previous Article | Next Article ![]()
Journal of Clinical Microbiology, July 2001, p. 2729-2731, Vol. 39, No. 7
Departments of Medicine and Pathology,
UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey
08901-0019
Received 19 January 2001/Returned for modification 28 March
2001/Accepted 3 May 2001
Although imipenem has in vitro activity against Enterococcus
faecalis and Food and Drug Administration-approved indications for treatment of infections caused by this microorganism, there are no
NCCLS guidelines for susceptibility testing of imipenem versus
enterococci. Therefore, the in vitro activities of penicillin, ampicillin, imipenem, and vancomycin against 201 blood isolates of
E. faecalis and 24 blood isolates of Enterococcus
faecium were compared. The susceptibility of isolates to
penicillin or ampicillin accurately predicted the in vitro activity of
imipenem. Since the susceptibility of enterococci to imipenem can be
predicted by the results obtained by testing of penicillin or
ampicillin, testing of imipenem by clinical laboratories probably is
not necessary.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.7.2729-2731.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Comparative Evaluation of Penicillin, Ampicillin, and Imipenem
MICs and Susceptibility Breakpoints for Vancomycin-Susceptible and
Vancomycin-Resistant Enterococcus faecalis and
Enterococcus faecium
*
Mailing address: Departments of Medicine and
Pathology, UMDNJ-Robert Wood Johnson Medical School, 1 Robert
Wood Johnson Pl., New Brunswick, NJ 08901-0019. Phone: (732)
235-7713. Fax: (732) 235-7951. E-mail: weinstei{at}umdnj.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»